Novo, Lilly Weight loss drugs should be the first choice for obesity treatment, European doctors say
Submitted by Nancy Lapid (Reuters) -Novo Nordisk and Eli Lilly’s most popular weight loss medication should be the first medicines to treat doctors to treat obesity and its complications, the European Medical Association advised Thursday. Semaglutid, the active Novo Wegovy and Ozempic and Tyzepatide, sold as Zepbound and Mounjar, Lilly, are so effective that they … Read more